Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the ClinicTacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic
Tacalyx Appoints Jean Engela as Chief Executive Officer to Spearhead Next Phase of GrowthBerlin, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tacalyx, a privately held biotech company focused on developing novel TACA (Tumour Associated Carbohydrate Antigens) cancer therapies, announces the appointment of Jean Engela as Chief Executive Officer. Jean Engela brings more than two decades of experience in drug research and development, with a proven track record of leading organisations and assets through key phase transitions and scaling from discovery to clinical stages. The company’s co-founder and former CEO, Dr. Peter Sondermann, will continue to drive scientific innovation at Tacalyx as Chief Scientific Officer.
